Ask about this productRelated genes to: P2RX1 Blocking Peptide
- Gene:
- P2RX1 NIH gene
- Name:
- purinergic receptor P2X 1
- Previous symbol:
- -
- Synonyms:
- P2X1
- Chromosome:
- 17p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1997-01-16
- Date modifiied:
- 2016-02-05
Related products to: P2RX1 Blocking Peptide
Related articles to: P2RX1 Blocking Peptide
- Gastric cancer remains a major cause of cancer-related mortality worldwide, highlighting the need for an improved understanding of its molecular mechanisms. Purinergic and glutamatergic signaling pathways, immune checkpoint molecules, and oxidative stress are thought to contribute to tumor biology; however, their combined evaluation in gastric cancer is limited. - Source: PubMed
Publication date: 2026/07/09
Coskun HakkiTuncbilek ZuhalGenc Husnu CagriKaya Gulcihan CinarTas Ayca - We aim to elucidate the impact of endometriomas on oocyte developmental competence and identify genetic alterations that may influence ICSI success rates in women of different ages. - Source: PubMed
Publication date: 2026/07/16
Kordowitzki PawelKochan JoannaWyroba Jakub - Purinergic P2X receptors () play key roles in neuroinflammatory processes through ATP-gated ion channel signaling. Dysregulation of receptor activity has been implicated in maternal immune activation, mitochondrial dysfunction, oxidative stress, and synaptic abnormalities associated with autism spectrum disorder (ASD). Despite increasing mechanistic evidence, the contribution of gene variants to ASD remains poorly understood. - Source: PubMed
Publication date: 2026/07/18
Ünsel-Bolat GülBolat Hilmi - Fibromyalgia (FM) is a chronic pain syndrome characterized by central sensitization, in which glutamatergic and purinergic signaling pathways are thought to play critical roles. This study aimed to evaluate the diagnostic potential of serum glutamate ionotropic receptor N-methyl-D-aspartate type subunit 1 (GRIN1), purinergic receptor P2X 1 (P2RX1), and purinergic receptor P2Y 2 (P2RY2) levels in patients with FM. A total of 93 newly diagnosed FM patients and 93 age- and sex-matched healthy controls were included in the study. Serum levels of GRIN1, P2RX1, and P2RY2 were measured using enzyme-linked immunosorbent assay (ELISA). Receiver operating characteristic (ROC) curve analysis was performed to assess the diagnostic performance of these biomarkers. ROC analysis demonstrated good diagnostic accuracy for all three biomarkers. The area under the curve (AUC) values were 0.817 for GRIN1, 0.778 for P2RX1, and 0.842 for P2RY2 ( < 0.001 for all). At optimal cut-off values, GRIN1, P2RX1, and P2RY2 showed sensitivities of 91.4%, 78.5%, and 92.5%, and specificities of 72.00%, 75.3%, and 80.6%, respectively. Serum GRIN1, P2RX1, and P2RY2 levels exhibit strong diagnostic performance in FM and may serve as promising biomarkers reflecting altered glutamatergic and purinergic signaling in disease pathophysiology. - Source: PubMed
Publication date: 2026/03/31
Dogan Sevil CeyhanKaya Gülcihan CinarTuncbilek ZuhalAtas MertTas Ayca - BACKGROUND: Tumour necrosis factor receptor-associated factor 7 (TRAF7), an E3 ubiquitin ligase, regulates multiple signalling pathways through posttranslational modifications. However, its role in acute myeloid leukaemia (AML) remains controversial and poorly understood. METHODS: Analysis of public AML datasets and validation using in-house samples were conducted to evaluate TRAF7 expression in bone marrow samples from AML patients and to assess its potential as a prognostic marker. Gain- and loss-of-function studies were performed in AML cell lines, primary CD34+ cells and a xenograft mouse model to characterize the role of TRAF7 in AML. RNA sequencing was employed to elucidate the mechanisms underlying the pro-leukaemic activity of TRAF7, and a ubiquitination assay was used to identify the substrate of TRAF7. RESULTS: TRAF7 is highly expressed in AML, particularly in the M5 subtype, and its upregulation serves as a novel independent prognostic marker for poor clinical outcomes. Functional studies demonstrate that TRAF7 promotes AML cell proliferation in vitro and leukaemogenesis in a human AML xenograft model. Mechanistically, TRAF7 interacts with TWIST1 and mediates its K63-linked polyubiquitination, enhancing TWIST1 nuclear localization. TWIST1 directly transcriptionally activates P2RX1, which increases mitochondrial calcium levels, respiratory activity, and ATP production, thereby fuelling leukaemic growth. CONCLUSIONS: Taken together, our study identifies TRAF7 as a novel tumour promoter in AML via the TWIST1–P2RX1-calcium axis, highlighting its role as a prognostic biomarker. Although TRAF7 represents a potential therapeutic target, its clinical applicability remains hypothetical in the absence of direct inhibitor studies. - Source: PubMed
Publication date: 2026/04/01
Shi CuijuanZhu WenqiYou NaZhang PeiwenHuang WanlingRen QianWang NanMa Xiaotong